ProKidney Corp
Change company Symbol lookup
Select an option...
PROK ProKidney Corp
BFS Saul Centers Inc
ABB Abb Ltd
BURL Burlington Stores Inc
TNEN True North Energy Corp
H Hyatt Hotels Corp
ACEL Accel Entertainment Inc
USLM United States Lime & Minerals Inc
BWEN Broadwind Inc
EQIX Equinix Inc
Go

Company profile

ProKidney Corp., formerly Social Capital Suvretta Holdings Corp. III, is a clinical-stage biotechnology company. The Company is focused on developing a cell therapy platform capable of treating multiple chronic kidney diseases (CKD) using a patient’s own cells isolated from the patient intended for treatment. Its lead product candidate, Renal Autologous Cell Therapy (REACT), is designed to stabilize or improve kidney function in a CKD patient's diseased kidneys. REACT is a product that includes selected renal cells (SRCs) prepared from a patient’s own, autologous, renal cells. The Company is focused on conducting a Phase III development program and multiple Phase II clinical trials for REACT in subjects with moderate to severe diabetic kidney disease.

The symbol you entered, DNAC, changed to PROK.

Closing Price
$7.42
Day's Change
0.38 (5.40%)
Bid
--
Ask
--
B/A Size
--
Day's High
7.66
Day's Low
6.23
Volume
(Below Average)
Volume:
35,775

10-day average volume:
40,242
35,775

There is no peer information for PROK.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.